UPS: Opportunities and challenges for gastric cancer treatment

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Gastric cancer is a leading cause of cancer mortality globally, with limited therapeutic options.
• The ubiquitin-proteasome system (UPS), crucial for protein homeostasis, is implicated in gastric cancer (GC) development.
• Dysregulation of UPS contributes to GC tumorigenesis, highlighting UPS components as potential therapeutic targets.

Purpose of the Study:

• To analyze aberrant enzyme expression within the UPS in gastric cancer.
• To identify specific E3 ligase enzymes suitable for Proteolysis-Targeting Chimera (PROTAC) drug development.
• To contribute to the advancement of UPS modulators and PROTAC technology for GC therapy.

Main Methods:

• Review and analysis of existing literature on UPS enzyme expression in gastric cancer.
• Identification and summary of E3 ligases involved in GC pathogenesis.
• Exploration of the potential of these E3 ligases in PROTAC-mediated protein degradation strategies.

Main Results:

• Evidence suggests UPS enzyme imbalance is a key factor in GC tumorigenesis.
• Specific E3 ligases show promise for targeted degradation strategies.
• PROTAC technology utilizing UPS is an emerging and effective approach in cancer therapy.

Conclusions:

• Modulating UPS enzymes and proteasome presents a viable strategy for GC targeted therapy.
• Identifying suitable E3 ligases is critical for developing effective PROTAC-based therapeutics for gastric cancer.
• This research supports the development of novel UPS modulators and PROTACs for improved gastric cancer treatment outcomes.